Legend Biotech Analyst Price Targets

Wall Street analyst price targets and consensus rating for Legend Biotech (LEGN).

Price Target Range — 12 Quarters

Analyst Consensus — 15 Analysts

11Buy

4Hold

Consensus RatingOverweight# Analysts15Avg. Consensus PT$64Upside to Avg. PT+193.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 13, 2026	Barclays	Etzer Darout	PT Cut	Overweight	$74→$68
Oct 9, 2026	JP Morgan	Jessica Fye	PT Cut	Neutral	$35→$33
Oct 8, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$58→$56
Sep 30, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$65
Sep 11, 2026	Barclays	Etzer Darout	PT Cut	Overweight	$78→$74
Sep 4, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$65
Aug 12, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Overweight	$48→$49
Aug 12, 2026	TD Cowen	Yaron Werber	PT Cut	Hold	$29→$24
Aug 12, 2026	Oppenheimer	Trevor Allred	Downgrade	Outperform→Perform	$75→$40
Aug 12, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$59→$58
Aug 12, 2026	Barclays	Etzer Darout	PT Cut	Overweight	$80→$78
Jul 28, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$65
Jul 27, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$63→$59
Jul 24, 2026	UBS	Ashwani Verma	Downgrade	Buy→Neutral	$49→$28
Jul 13, 2026	JP Morgan	Jessica Fye	Reinstates	Neutral	$35
Jul 7, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$64→$63
Jun 3, 2026	UBS	Ashwani Verma	PT Raise	Buy	$31→$49
Jun 3, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$50→$65
May 18, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$50
May 13, 2026	TD Cowen	Yaron Werber	PT Raise	Hold	$21→$29

Analyst Ratings News

PRO
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $68

Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $74 to $68.

Benzinga Newsdesk

PRO
JP Morgan Maintains Neutral on Legend Biotech, Lowers Price Target to $33

JP Morgan analyst Jessica Fye maintains Legend Biotech (NASDAQ:LEGN) with a Neutral and lowers the price target from $35 to $33.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $56

RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $58 to $56.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $65 price target.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $74

Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $78 to $74.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $65 price target.

Benzinga Newsdesk

Legend Biotech Corp

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Legend Biotech Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $68

PRO
JP Morgan Maintains Neutral on Legend Biotech, Lowers Price Target to $33

PRO
RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $56

PRO
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target

PRO
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $74

PRO
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target

People Also Watch

People Also Watch

Legend Biotech Corp

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Legend Biotech Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Maintains Overweight on Legend Biotech, Lowers Price Target to $68

PROJP Morgan Maintains Neutral on Legend Biotech, Lowers Price Target to $33

PRORBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $56

PROHC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target

PROBarclays Maintains Overweight on Legend Biotech, Lowers Price Target to $74

PROHC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target

People Also Watch

People Also Watch

PRO
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $68

PRO
JP Morgan Maintains Neutral on Legend Biotech, Lowers Price Target to $33

PRO
RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $56

PRO
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target

PRO
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $74

PRO
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target